Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leucine for Inflammation-Induced Depression
NCT03557684Phase 1Terminated
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2018
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial (4 arms), sponsored by University of California, Los Angeles. Primary endpoint: Change in Depressed Mood From Baseline at 6 hours. Started Sep 2018; status: terminated.
Beyond the preview
Go deeper on NCT03557684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557684.